Neogap enrols first patient in Phase I/II clinical trial of personalised immunotherapy for colorectal cancer
Swedish biotechnology company Neogap Therapeutics, specialising in personalised immunotherapy for cancer treatment, has announced the successful enrolment of its first patient in a Phase I/II clinical trial targeting advanced colorectal cancer.Neogap has included the first patient in their first-in-human trial with the cell therapy product pTTL (personalised Tumour Trained Lymphocytes). Production of personalised EpiTCer[®] beads for the patient has been initiated. These beads play a crucial role in the pTTL therapy by facilitating the training of the T cells to recognise neoantigens and